# A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

> **NCT01790100** · PHASE2 · COMPLETED · sponsor: **Alios Biopharma Inc.** · enrollment: 20 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** VX-135
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01790100
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2014-06-30
- **Final completion:** 2014-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01790100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01790100, "A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01790100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*